The Prognostic Impact of Tumor Size in Papillary Thyroid Carcinoma is Modified by Age

Tran, Bryan; Roshan, David; Abraham, Earl; Wang, Laura Y.; Garibotto, Natalia; Wykes, James; Campbell, Peter; Ebrahimi, Ardalan

doi:10.1089/thy.2017.0607

Cited by 48 publications

(30 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although previous studies have identified the effect of tumor size on the risk of BM from RCC, our analysis revealed for the first time that age significantly affected the risk of developing BM from RCC and the impact of age was limited to patients with primary tumor size ≥ 7 cm. Tran et al [17] have also explored the interaction effect between tumor size and age on the prognosis of patients with papillary thyroid carcinoma and found that the impact of tumor size BioMed Research International on RFS was limited to patients aged ≥55 years. However, to our knowledge, there are no previous studies analyzing the interaction effect between tumor size and age on the risk of BM from RCC patients.…”

Section: Discussionmentioning

confidence: 99%

Risk Factors for Brain Metastases in Patients with Renal Cell Carcinoma

Chen

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Background. Patients with brain metastases (BM) from renal cell carcinoma (RCC) were considered to experience a poor prognosis. However, there is little knowledge on the risk factors for BM from RCC at diagnosis. This study was aimed at exploring the risk factors for patients with BM from RCC and the interaction among these risk factors. Methods. A total of 38759 cases of RCC were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Risk factors for BM from RCC were evaluated by univariate and multivariate logistic regression analyses. Interaction effect between age and tumor size was tested.Results. There was a significant difference in univariate analysis, including T stage, tumor size, grades III and IV, lymph node metastasis, bone metastasis, liver metastasis, lung metastasis, and surgery. There was a significant difference in multivariate analysis, including age, T stage, tumor size < 10 cm, grade IV, lymph node metastasis, bone metastasis, lung metastasis, and surgery. Patients older than 70 had 0.653-fold lower risk of developing BM compared with those younger than 70. Patients with tumor size ≥ 4 cm and <10 cm had higher risk of developing BM compared with those < 4 cm. The larger the tumor size, the higher the incidence of BM from RCC in those whose tumor size was less than 10 cm. An interaction test between the tumor size and age on brain metastasis was statistically significant in the crude analysis (P = 0:0114) and model II analysis (P = 0:0248) but not in model I analysis (P = 0:1136). Although age significantly affected the risk of BM from RCC, impact of age on the risk of developing BM from RCC was limited to patients with tumor size ≥ 7 cm. Conclusion. Both tumor size and age were independent risk factors for brain metastases in patients with RCC. The impact of age on the risk of developing BM from RCC was limited to patients with tumor size ≥ 7 cm. Patients with a larger tumor size and younger age might have the higher risk of developing BM at diagnosis of RCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Risk Factors for Brain Metastases in Patients with Renal Cell Carcinoma

Chen

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…In this study, we found that patients with lower levels of serum Apo-A1 are more likely to be diagnosed with larger tumor sizes of PTC in a male cohort, especially in a young male subgroup (< 55 years old), this correlation was not seen when it comes to the female cohort. Tumor size has been demonstrated as an independent predictor of recurrence in PTC in previous study (tumors > 2 cm associated with higher risk of recurrence than those ≤ 2 cm ), [14] which indicates Apo-A1 is an protective biomarkers for male PTC patients.…”

Section: Discussionmentioning

confidence: 82%

Apolipoprotein A1 is A Protective Factor for Male Papillary Thyroid Cancer Patients. A Cross-Sectional Study of Single Academic Center in China.

Wang

Zhan-qiang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Papillary thyroid cancer (PTC) is the most common type of thyroid cancer and the incidence of PTC has continued to increase over the past decades. Many studies have shown that obesity is an independent risk factor for PTC and obese PTC patients tend to have a relative larger tumor size and higher grade of tumor stage. Obesity is associated with disordered lipid metabolism and the relationship between serum lipids and PTC remains unclear. Therefore, this study aimed to investigate the association between serum lipid level and PTC.Methods: We retrospectively analyzed 1018 PTC patients diagnosed and treated in our hospital, all these cases were first diagnosed with PTC and had complete clinical information including ultrasound reports before surgery, serum lipid (CHOL, TG, HDL-c, LDL-c, Apo-A1, Apo-B, Apo-E) results, surgical records and pathological reports. Results: None of these lipid markers were associated with tumor size in the whole cohort and in the female group. In the male group, on crude analysis, Apo-A1 showed a marginally significant association with tumor size, [OR=0.158 (0.021-1.777)], p=0.072. After adjusting for age and multifocality, Apo-A1 showed a significant association with tumor size [OR=0.126 (0.016-0.974)], p=0.047. This association become more apparent in a young male subgroup, [OR=0.051 (0.005-0.497)], p=0.009. CHOL, TG, HDL-c, LDL-c, Apo-B, Apo-E did not show significant association with tumor size. As for LNM, neither in the male group nor in the female group were found to be associated with any serum lipid biomarkers.Conclusion: As PTC incidences continues to increase, our finding a negative association between PTC and apoA-1 imply that these lipids are protective factors for male PTC patients and provide us new clues about PTC and lipid metabolism, which may contribute to further investigation concerning diagnosing and preventing this most common type of thyroid cancer.

show abstract

“…In this study, we found that patients with lower levels of serum Apo-A1 and Lp (a) are more likely to be diagnosed with larger tumor sizes of PTC in a male cohort, especially in a young male subgroup (< 55 years old), this correlation was not seen when it comes to the female cohort. Tumor size has been demonstrated as an independent predictor of recurrence in PTC in previous study (tumors > 2 cm associated with higher risk of recurrence than those ≤ 2 cm ), [14] which indicates Apo-A1 and Lp (a) are two protective biomarkers for male PTC patients.…”

Section: Discussionmentioning

confidence: 84%

Apolipoprotein A1 and lipoprotein(a) are protective factors for male papillary thyroid cancer patients. A cross-sectional study of single academic center in China.

Zhang

et al. 2020

Preprint

View full text Add to dashboard Cite

KEYWORDSPapillary thyroid cancer, serum lipid level, tumor size, lipid metabolism 2 Abstract Background: Papillary thyroid cancer (PTC) is the most common type of thyroid cancer and the incidence of PTC continued to increase over the past decades. Many studies showed that obesity is an independent risk factor for PTC and obese PTC patients tend to have a relative larger tumor size and higher grade of tumor stage. Obesity is closely related with lipid metabolism, while the correlation between serum lipid and PTC remains unclear. Therefore, this study aimed to investigate the association between serum lipid level and PTC.Methods: We retrospectively analyzed 1018 PTC patients diagnosed and treated in our hospital, all these cases were first diagnosed with PTC and had complete clinical information including ultrasound reports before surgery, serum lipid (CHOL, TG, HDL-c, LDL-c, Apo-A1, Apo-B, Apo-E, Lp (a)) results, surgical records and pathological reports.Results: All these serum lipid biomarkers did not associated with tumor size in the female group. In the male group, on crude analysis, Apo-A1 and Lp (a) showed a marginally significant association with tumor size OR and 95% CI 0.158 (0.021-1.777), p=0.072; 0.997 (0.993-1.000) p=0.082 respectively.After adjusting for age and multifocality, Apo-A1 and Lp (a) showed a significant association with

show abstract

The Prognostic Impact of Tumor Size in Papillary Thyroid Carcinoma is Modified by Age

Cited by 48 publications

References 23 publications

Risk Factors for Brain Metastases in Patients with Renal Cell Carcinoma

Risk Factors for Brain Metastases in Patients with Renal Cell Carcinoma

Apolipoprotein A1 is A Protective Factor for Male Papillary Thyroid Cancer Patients. A Cross-Sectional Study of Single Academic Center in China.

Apolipoprotein A1 and lipoprotein(a) are protective factors for male papillary thyroid cancer patients. A cross-sectional study of single academic center in China.

Contact Info

Product

Resources

About